Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NMTC vs PEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

PEN Overall Winner 6-Pillar Tally: NMTC 1 – 5 PEN Matrix Metrics: NMTC 1 – 9 PEN

As of Nov 20, 2026, Penumbra, Inc. (PEN) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas PEN carries 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin).

  • Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile PEN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMTC vs PEN
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03
PEN NYSE Head-to-Head Winner
Penumbra, Inc.
Surgical & Medical Instruments & Apparatus
$319.12
-0.28% 1D
Market Cap $12.6B
TTM Revenue $1.56B
Forward P/E 53.1x
Beta / 30D Vol 0.10β · 10% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 46.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.2%) with fading momentum, RSI 45
RSI-14: 45.0 · SMA20: $320.94 · SMA50: $320.21

6-Pillar Scorecard Institutional Category Breakdown (NMTC 1 – 5 PEN)

Columns: Metric · NMTC · PEN
1. Valuation Multiples PEN
Forward P/E N/M 53.1x
Trailing P/E N/M 80.6x
PEG Ratio N/M 3.61x
EV / Revenue 0.3x 8.1x
2. Growth & Scale NMTC
Revenue Growth (YoY) +16.3% +15.6%
Earnings Growth (YoY) +0.0% -8.5%
TTM Revenue (USD) $12M $1.56B
Market Cap $6.1M $12.6B
3. Profitability & Quality PEN
Gross Margin 23.0% 68.0%
Operating Margin -63.4% 12.1%
Net Profit Margin -59.7% 10.1%
Return on Equity (ROE) -124.7% 10.7%
4. Balance Sheet & Cash Flow PEN
Cash Generation (TTM) -$7.6M $200M
Cash Flow Margin -60.7% 12.8%
Net Cash / Leverage $2.6M Net Cash $45M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PEN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 207.7% (96th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat PEN
OpEx & R&D Intensity N/A 55.9% of Rev ($872M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMTC (1) vs PEN (9)
Institutional Metric NMTC PEN Criterion Row Edge
Market Capitalization
Scale
$6.1M $12.6B Larger Scale PEN
Trailing P/E Ratio
Valuation
N/M 80.6x Lower Multiple PEN
Forward P/E Ratio
Valuation
N/M 53.1x Lower Multiple PEN
Revenue Growth (YoY)
Growth
+16.3% +15.6% Higher Growth NMTC
Operating Margin (TTM)
Profitability
-63.4% 12.1% Higher Margin PEN
Net Profit Margin
Profitability
-59.7% 10.1% Higher Margin PEN
Return on Equity (ROE)
Capital Efficiency
-124.7% 10.7% Higher ROE PEN
52-Week Range Position
Momentum
2% ($1–$5) 50% ($277–$362) Stronger Trend PEN
Beta / 30D Volatility
Risk Regime
1.55β · 105% Vol 0.10β · 10% Vol Lower Realized Risk PEN
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite PEN
Trailing 12M Revenue (USD)
Operating Scale
$12M $1.56B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.0% 68.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev 3.61x PEG · 8.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($2.6M Net Cash) $200M ($45M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PEN +31.66 pp
NMTC: -33.46% · PEN: -1.8%
3M Horizon PEN +68.1 pp
NMTC: -69.53% · PEN: -1.43%
6M Horizon PEN +79.42 pp
NMTC: -82.33% · PEN: -2.91%
1Y Horizon PEN +9.21 pp
NMTC: +3.49% · PEN: +12.7%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NMTC Revenue PEN Revenue NMTC Op. Margin PEN Op. Margin Margin Leader
FY2018 N/A $440M N/A -0.2% PEN
FY2019 N/A $550M N/A 8.7% PEN
FY2020 N/A $560M N/A -6.9% PEN
FY2021 $0M $750M -5735.9% -1.0% PEN
FY2022 $0M $850M -5860.2% 0.7% PEN
FY2023 $0M $1.06B -612.3% 6.9% PEN
FY2024 $0M $1.19B -344.3% 0.8% PEN
FY2025 $10M $1.40B -46.5% 13.5% PEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 207.7%
IV Percentile 96th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact PEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $319.69 · IV 30.1%

PEN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($31,969)

Compare $31,969 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 30.1% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $290 / $260 Bull Put Spread

Sell 1x $290P · Buy 1x $260P · 31d

Net Entry $140 Credit
Max Credit / Yield +$140 (+4.9% RoM)
Max Risk / Buffer -9.7% Cushion ($2,860 Mgn)
5d Edge & Liquidity 81% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $320 / $300 Bear Put Spread

Buy 1x $320P · Sell 1x $300P · 31d

Net Entry $750 Debit
T+5d @ -5% Drop +$425 (+57%)
Max Risk / Buffer $750 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PEN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.6B market capitalization and 12.1% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($872M)
90D Engineering Disclosures 0 Published

Investor FAQ NMTC vs PEN Key Questions & Quantitative Answers

As of Nov 20, 2026, Penumbra, Inc. (PEN) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas PEN carries 52.2/100 (HOLD) at $319.12 (53.1x Forward P/E, 12.1% operating margin). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile PEN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with PEN at +15.6% YoY revenue growth and -8.5% YoY earnings growth on $1.56B TTM revenue (68.0% gross margin, 12.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NMTC cumulative revenue shifted N/A while PEN shifted +218.2%. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($872M) (0 disclosures) for PEN.

PEN screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas PEN trades at 53.1x Forward P/E, 80.6x Trailing P/E, 3.61x PEG, and 8.1x EV/Revenue (12.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus PEN (10.7% ROE) capital efficiency.

In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, PEN carries 207.7% implied volatility (96th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.10β · 10% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.